Stage III non-small-cell lung cancer

Petrella, Francesco; Rizzo, Stefania; Attili, Ilaria; Passaro, Antonio; Zilli, Thomas; Martucci, Francesco; Bonomo, Luca; Del Grande, Filippo; Casiraghi, Monica; De Marinis, Filippo; Spaggiari, Lorenzo

doi:10.3390/curroncol30030239

Back

Journal article

Stage III non-small-cell lung cancer : an overview of treatment options

Petrella, Francesco ORCID Department of Thoracic Surgery, European Institute of Oncology IRCCS, Milan, Italy - Department of Oncology and Hemato‐Oncology, University of Milan, Milan, Italy
Rizzo, Stefania ORCID Service of Radiology, Imaging Institute of Southern Switzerland (IIMSI), EOC, Lugano, Switzerland - Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
Attili, Ilaria Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy
Passaro, Antonio ORCID Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy
Zilli, Thomas Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Radiation Oncology, Oncological Institute of Southern Switzerland, EOC, Bellinzona, Switzerland - Faculty of Medicine, University of Geneva, Geneva, Switzerland
Martucci, Francesco Radiation Oncology, Oncological Institute of Southern Switzerland, EOC, Bellinzona, Switzerland
Bonomo, Luca Service of Radiology, Imaging Institute of Southern Switzerland (IIMSI), EOC, Lugano, Switzerland
Del Grande, Filippo ORCID Service of Radiology, Imaging Institute of Southern Switzerland (IIMSI), EOC, Lugano, Switzerland - Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
Casiraghi, Monica ORCID Department of Thoracic Surgery, European Institute of Oncology IRCCS, Milan, Italy - Department of Oncology and Hemato‐Oncology, University of Milan, Milan, Italy
De Marinis, Filippo Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy
Spaggiari, Lorenzo ORCID Department of Thoracic Surgery, European Institute of Oncology IRCCS, Milan, Italy - Department of Oncology and Hemato‐Oncology, University of Milan, Milan, Italy

2023

Published in:

Current oncology. - 2023, vol. 30 , no. 3, p. 3160-3175

English Lung cancer is the second-most commonly diagnosed cancer and the leading cause of cancer death worldwide. The most common histological type is non-small-cell lung cancer, accounting for 85% of all lung cancer cases. About one out of three new cases of non-small-cell lung cancer are diagnosed at a locally advanced stage—mainly stage III—consisting of a widely heterogeneous group of patients presenting significant differences in terms of tumor volume, local diffusion, and lymph nodal involvement. Stage III NSCLC therapy is based on the pivotal role of multimodal treatment, including surgery, radiotherapy, and a wide-ranging option of systemic treatments. Radical surgery is indicated in the case of hilar lymphnodal involvement or single station mediastinal ipsilateral involvement, possibly after neoadjuvant chemotherapy; the best appropriate treatment for multistation mediastinal lymph node involvement still represents a matter of debate. Although the main scope of treatments in this setting is potentially curative, the overall survival rates are still poor, ranging from 36% to 26% and 13% in stages IIIA, IIIB, and IIIC, respectively. The aim of this article is to provide an up-to-date, comprehensive overview of the state-of-the-art treatments for stage III non-small-cell lung cancer.

Collections